EPID Research acts as a single point of contact for pharmaceutical companies.
We offer services according to our clients' needs whether they are regulatory needs, related to market access, safety or research and development.

Our design and coordination services include Real-World Evidence development and consultancy, study coordination and conduct of feasibility studies.

We offer pharmacoepidemiological studies including post-authorization safety studies (PASS), drug utilization studies and relative effectiveness studies. Real-World Evidence is typically used in post-authorization phase of drug development. However, it can be used already in earlier phases to give insights and evidence of disease epidemiology and drug positioning.

Furthermore, we also provide services such as health economics studies, literature reviews, meta-analysis and support for risk management plans. Our methods can also be utilised in benefit to risk ratio assessments and as support for pricing and reimbursement decisions. 

Sources of data

For each study we conduct, we evaluate and select the best suitable data sources.

One of the main sources for data is different kind of health care registers. National registers often contain data on prescriptions, medical births, hospital care and causes of death together with demographic data. Regional registers contain for example electronic medical records and laboratory results. Quality registers, on the other hand, are specific to certain therapeutic areas. Furthermore, biobanks collect and store tissue samples and related data.

Our extensive selection of data sources further includes publications, research cohorts, insurance claims and General Practitioner (GP) data.

Pharmacoepidemiological studies

Our offering on pharmacoepidemiological studies includes:
Post-authorization safety studies (PASS)
Drug utilization studies (DU)
Relative effectiveness studies

Benefits of RWE studies

One of the benefits of Real-World Evidence is that it can build on already existing data that is of high quality. Real-World Evidence has the possibility to provide nationwide coverage with high number of patients. Importantly, Real-World Evidence enables the investigation of rare outcomes, special populations, pregnancies and their outcomes, and orphan drugs. All in all, Real-World Evidence brings huge savings in resources, time and money.

Code of Conduct

EPID Research is a partner centre of the ENCePP, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, a scientific network coordinated by the European Medicines Agency. 
EPID Research commits to adhere to the rules of the ENCePP Code of Conduct in their entirety. Studies conducted by EPID Research will be registered into the EU PAS Register. A clear summary of the main results of the studies, whether positive or negative and including results from prematurely terminated studies, will always be made available to the public.

Coordination services

EPID Research acts as a single point of contact for pharmaceutical companies. We coordinate all study actions with data holders as well as with possible partners.
We are experienced in conducting complex multi-country studies which involve various parties including pharma companies, academic partners and clinical experts. In these kind of large projects central coordination is essential and EPID Research is experienced in this role.

Our coordination services bring the following benefits:
  • Study conduct and study design are based on EPID Research’s existing expertise
  • EPID Research’s global network of research partners can be utilised
  • Studies are fully tailored to the client's medical and commercial needs
  • The best available scientific expertise and Real-World Data sources can be utilised
  • Client has full control and visibility while day-to-day management is outsourced to EPID Research

Expertise in Nordic registers

Real-World Evidence based on register data originating from routine medical practice is essential in modern, high quality pharmacoepidemiological research. Nordic registers are exceptional in their long history, population-wide coverage and linkage. We concentrate on four Nordic countries including Finland, Sweden, Norway and Denmark. Their combined population is around 26 million people. EPID Research has solid expertise and experience in these Nordic registers.

Multiple levels of data

Multiple levels of data are available for conducting pharmacoepidemiological studies in the Nordics. National healthcare registers, quality registers and hospital data combined with regional biobank data offer vast possibilities for different types of pharmacoepidemiological studies. All Nordic citizens have unique personal identification numbers, which enable linkage between all different registers. Linking different data sources enables large cohorts and results in rich study data. This data can be further enriched for example with data from research cohorts or publications.

National healthcare registers

1) outpatient hospital visits and day surgeries 2) nationwide coverage
The Nordic national healthcare registers have a population-wide coverage within each country. Inclusion is not based on incomes, insurances or other social statuses, and the overall quality of the registers is high. The main Nordic registers used in pharmacoepidemiological studies and their year of establishment are introduced in the table above.

Key benefits

  • Nationwide data
  • Data linkage between registers
  • Large study cohorts
  • Long history
If you are interested in using Real-World Evidence and Nordic registers, EPID Research has solid experience in conducting research using these registers and is happy to partner with you.
Are you interested in learning more about how our RWE solutions can help you in your drug development and surveillance? Our team of experts is eager to discuss your specific needs. To learn more, please contact us at